News headlines about Insulet (NASDAQ:PODD) have trended somewhat positive on Monday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 46.944106040613 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Swiss National Bank Has $6.82 Million Position in Insulet Co. (PODD) (americanbankingnews.com)
- Insulet’s (PODD) “Buy” Rating Reiterated at Jefferies Group (americanbankingnews.com)
- Insulet (PODD) PT Raised to $88.00 at Canaccord Genuity (americanbankingnews.com)
- 8 Stocks Getting Multiple Analyst Upgrades and Downgrades After Earnings and News (msn.com)
- Equities Analysts Offer Predictions for Insulet Co.’s Q4 2019 Earnings (PODD) (americanbankingnews.com)
Insulet (PODD) opened at $75.55 on Monday. Insulet has a 1-year low of $38.43 and a 1-year high of $83.56. The firm has a market cap of $4,411.44, a P/E ratio of -164.24 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.
Several research firms have recently issued reports on PODD. Jefferies Group reiterated a “buy” rating and set a $90.00 target price on shares of Insulet in a report on Friday. Oppenheimer set a $82.00 target price on shares of Insulet and gave the company a “hold” rating in a report on Thursday. Stephens reiterated an “equal weight” rating and set a $81.00 target price (up from $60.00) on shares of Insulet in a report on Thursday. Canaccord Genuity lifted their target price on shares of Insulet from $78.00 to $88.00 and gave the company a “neutral” rating in a report on Friday. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $87.00 target price (up from $76.00) on shares of Insulet in a report on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $72.19.
ILLEGAL ACTIVITY WARNING: “Insulet (PODD) Given Daily News Impact Score of 0.16” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3222251/insulet-podd-given-daily-news-impact-score-of-0-16.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.